Global Monoamine Oxidase Inhibitors (MAOIs) Pipeline Insights Review 2015

. Buy Professional Pack-20 () with free prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/vt8jjk/monoamine_oxidase) has announced the addition of the "Monoamine Oxidase Inhibitors (MAOIs) -Pipeline Insights" report to their offering. Monoamine Oxidase Inhibitors (MAOIs) Pipeline Insights provides the in-depth analysis of the pipeline assets across the Monoamine Oxidase Inhibitors (MAOIs). Buy Bars online About Sporanox (Itraconazole) without Rx The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. http://md-opinion.blogspot.com About Diamox (Acetazolamide) with no prescription The Monoamine Oxidase Inhibitors (MAOIs) Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. Monoamine Oxidase Inhibitors (MAOIs) Pipeline Insights Report covers the Monoamine Oxidase Inhibitors (MAOIs) pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. Vantin (Cefpodoxime) The Report also provides Monoamine Oxidase Inhibitors (MAOIs) related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. About Encript without prescription The Report also highlights the discontinued and inactive projects in pipeline for Monoamine Oxidase Inhibitors (MAOIs). Scope - The report provides a Monoamine Oxidase Inhibitors (MAOIs) Landscape across the globe - The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the Monoamine Oxidase Inhibitors (MAOIs) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Monoamine Oxidase Inhibitors (MAOIs) and also provide company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery. - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit .researchandmarkets.com/research/vt8jjk/monoamine_oxidase

Amneal Launches Aripiprazole Oral Solution, One of the First Generic Liquid Forms Available for Abilify®

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals LLC (.amneal.com) today announced the launch of aripiprazole oral solution in 1 mg/mL strength, allowing prescribers to continue writing for the recently discontinued reference brand. About Risperdal (Risperidone) with free Rx The Amneal generic — one of the first liquid forms on the market — is an AA-rated, therapeutic equivalent to the discontinued Abilify® Oral Solution. Elavil (Amitriptyline) without prescription It is now shipping in 150 mL (5 fl oz) bottles through wholesalers, distributors and directly to the trade. “Healthcare providers can now continue prescribing a therapy they are comfortable with and in a form certain patients require,” explains Jim Luce, Amneal Executive Vice President of Sales & Marketing. About Ampicillin (Acillin) with free prescription “It’s a product that would otherwise be unavailable if not for the generic equivalent.” Annual U.S. Buy Elidel with no prescription sales of aripiprazole oral solution were $62.8 million as of June 2015, according to IMS Health. Visit prd02.apsiva.net/210/GenericCategory/Aripiprazole-pi.pdf for full prescribing information. About Amneal Pharmaceuticals LLC Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, vertically integrated across the entire supply chain from R&D to finished goods. About Reosto () with free prescription Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure, and strategic expansion opportunities — all contributing to its significant growth. Buy Arginine online The Company prides itself on its unwavering commitment to quality, strong business relationships, and innovative approach to maximizing value. http://mdreview.wordpress.com Amneal is privately held with U.S. headquarters in Bridgewater, New Jersey, and international headquarters in Zug, Switzerland. For more information, please visit .amneal.com. All trademarks are property of their respective owners.

New data show Spiolto Respimat provides meaningful quality of life improvements in COPD

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto® Respimat® (tiotropium/olodaterol) provides consistent, clinically meaningful improvements in quality of life versus placebo in patients with COPD*. Norvir (Ritonavir) with no Rx These data are published online in the journal Respiratory Medicine.1 For COPD patients, breathlessness, among other symptoms, limits their ability to keep active and has a negative impact on their daily lives. Buy Intagra (Sildenafil Citrate) without Rx As there is no cure for COPD, improving quality of life is a major goal of treatment. Prometrium (Progesterone) without prescription In COPD, quality of life is measured using the SGRQ†; a reduction in SGRQ score of 4 points or more is deemed clinically meaningful.2 The OTEMTO® trials show Spiolto® Respimat® provides a reduction in SGRQ total score of 4.67‡ versus placebo. “The improvement in quality of life provided by Spiolto® Respimat® in these trials could make a noticeable difference to the daily activity of COPD patients and enable them to maintain a more independent life,” said Dave Singh, Professor of clinical pharmacology and respiratory medicine, University of Manchester and lead investigator of the OTEMTO® trials. Doxazosin with free prescription “For example, this could mean that patients are able to walk up stairs without stopping, go out to socialise with friends or find it easier to wash and dress. Super Pack () with free Rx Essentially, the data show that patients feel much better.” Further data from the 1,600 patient OTEMTO® trials show Spiolto® Respimat® provides: clinically meaningful improvements in breathlessness compared to placebo (measured by a 1.62 point improvement in TDI focal score§), reflecting the meaningful quality of life benefits consistent improvements in lung function, breathlessness and quality of life compared to Spiriva® (tiotropium) a safety profile similar to Spiriva® or placebo. Buy Weightlifting Belts online Incidence of adverse events (AEs) was broadly similar across treatment groups, with a higher incidence of AEs leading to discontinuation in the placebo groups compared to the treatment groups OTEMTO® 1&2 build on the pivotal phase III TONADO® trials that demonstrated Spiolto® Respimat® provides significant improvements in lung function, breathlessness, quality of life and reduction in rescue medication use over Spiriva® Respimat® right from the initial disease stages when patients first need maintenance therapy.3,4 OTEMTO® 1&2 are part of the >15,000 patient TOviTO® Phase III clinical trial programme, one of the largest trial programmes conducted in COPD. U.S. http://anti-infectives-opinion.blogspot.com Food and Drug Administration (FDA) recently accepted for review a Supplemental New Drug Application (sNDA) to include the OTEMTO® quality of life data in the Stiolto™ Respimat®** label. For further information visit: newscentre.boehringer-ingelheim.com/education_hub1/respiratory.html OTEMTO® Respiratory Medicine publication: dx.doi.org/10.1016/j.rmed.2015.08.002 About Spiolto® Respimat® To date, Spiolto® Respimat® has gained approval in more than 20 EU/EEA countries, the US, Canada and Australia for use in the treatment of patients with COPD. Spiolto® Respimat® is built on tiotropium, the active ingredient in Spiriva® - the world’s most prescribed COPD maintenance treatment with over 40 million patient years of real life experience across all COPD severities.5 It is enhanced by olodaterol††, a unique and effective long-acting beta2-agonist with a fast onset of action,6 specifically designed to complement the efficacy of Spiriva®. Spiolto® is delivered by Respimat®, the only inhaler available that actively‡‡ delivers a unique mist, meaning the patient just needs to breathe in naturally for the medication to go deep into the lungs.7-13 Intended audiences This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. For ‘Notes to Editors’ and ‘References’ please visit: .boehringer-ingelheim.com/news/news_releases/press_releases/2015/17_august_2015_copd.html * Chronic obstructive pulmonary disease † St George’s Respiratory Questionnaire (SGRQ), a disease-specific patient-reported instrument that evaluates symptoms including frequency and duration of cough, wheezing and breathlessness ‡ SGRQ total score after 12 weeks of treatment in the combined data set of the 2 replicate studies OTEMTO®1 and OTEMTO® 2 § Transition dyspnoea index focal score after 12 weeks of treatment in the combined data set ** Spiolto® Respimat® is marketed as Stiolto™ Respimat® in the US and Inspiolto™ Respimat® in Canada †† Marketed as Striverdi® Respimat® ‡‡ Respimat® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation